DOCS Stock Overview
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.
Dr. Martens Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£2.34|
|52 Week High||UK£4.77|
|52 Week Low||UK£1.75|
|1 Month Change||-9.43%|
|3 Month Change||-1.60%|
|1 Year Change||-48.14%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-47.91%|
Recent News & Updates
Why Investors Shouldn't Be Surprised By Dr. Martens plc's (LON:DOCS) 26% Share Price Surge
Dr. Martens plc ( LON:DOCS ) shareholders would be excited to see that the share price has had a great month, posting a...
|DOCS||GB Luxury||GB Market|
Return vs Industry: DOCS underperformed the UK Luxury industry which returned -29.9% over the past year.
Return vs Market: DOCS underperformed the UK Market which returned -9.5% over the past year.
|DOCS Average Weekly Movement||9.9%|
|Luxury Industry Average Movement||8.3%|
|Market Average Movement||5.4%|
|10% most volatile stocks in GB Market||10.6%|
|10% least volatile stocks in GB Market||2.8%|
Stable Share Price: DOCS is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: DOCS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name.
Dr. Martens Fundamentals Summary
|DOCS fundamental statistics|
Is DOCS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DOCS income statement (TTM)|
|Cost of Revenue||UK£329.50m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Nov 24, 2022
|Earnings per share (EPS)||0.18|
|Net Profit Margin||19.95%|
How did DOCS perform over the long term?See historical performance and comparison
2.3%Current Dividend Yield
Is DOCS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DOCS?
Other financial metrics that can be useful for relative valuation.
|What is DOCS's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does DOCS's PE Ratio compare to its peers?
|DOCS PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
GAW Games Workshop Group
BRBY Burberry Group
COA Coats Group
DOCS Dr. Martens
Price-To-Earnings vs Peers: DOCS is good value based on its Price-To-Earnings Ratio (12.9x) compared to the peer average (13.5x).
Price to Earnings Ratio vs Industry
How does DOCS's PE Ratio compare vs other companies in the European Luxury Industry?
Price-To-Earnings vs Industry: DOCS is good value based on its Price-To-Earnings Ratio (12.9x) compared to the UK Luxury industry average (14.8x)
Price to Earnings Ratio vs Fair Ratio
What is DOCS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||12.9x|
|Fair PE Ratio||18.1x|
Price-To-Earnings vs Fair Ratio: DOCS is good value based on its Price-To-Earnings Ratio (12.9x) compared to the estimated Fair Price-To-Earnings Ratio (18.1x).
Share Price vs Fair Value
What is the Fair Price of DOCS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DOCS (£2.34) is trading below our estimate of fair value (£4.19)
Significantly Below Fair Value: DOCS is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: DOCS is poor value based on its PEG Ratio (1.1x)
Discover undervalued companies
How is Dr. Martens forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DOCS's forecast earnings growth (12.1% per year) is above the savings rate (0.9%).
Earnings vs Market: DOCS's earnings (12.1% per year) are forecast to grow faster than the UK market (10.9% per year).
High Growth Earnings: DOCS's earnings are forecast to grow, but not significantly.
Revenue vs Market: DOCS's revenue (13.1% per year) is forecast to grow faster than the UK market (4.1% per year).
High Growth Revenue: DOCS's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DOCS's Return on Equity is forecast to be high in 3 years time (34.7%)
Discover growth companies
How has Dr. Martens performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DOCS has high quality earnings.
Growing Profit Margin: DOCS's current net profit margins (19.9%) are higher than last year (4.5%).
Past Earnings Growth Analysis
Earnings Trend: DOCS has become profitable over the past 5 years, growing earnings by 41.6% per year.
Accelerating Growth: DOCS's earnings growth over the past year (422.2%) exceeds its 5-year average (41.6% per year).
Earnings vs Industry: DOCS earnings growth over the past year (422.2%) exceeded the Luxury industry 62.3%.
Return on Equity
High ROE: DOCS's Return on Equity (55.2%) is considered outstanding.
Discover strong past performing companies
How is Dr. Martens's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: DOCS's short term assets (£443.6M) exceed its short term liabilities (£155.0M).
Long Term Liabilities: DOCS's short term assets (£443.6M) exceed its long term liabilities (£375.9M).
Debt to Equity History and Analysis
Debt Level: DOCS's net debt to equity ratio (16.1%) is considered satisfactory.
Reducing Debt: DOCS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: DOCS's debt is well covered by operating cash flow (65.6%).
Interest Coverage: DOCS's interest payments on its debt are well covered by EBIT (15.1x coverage).
Discover healthy companies
What is Dr. Martens's current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DOCS's dividend (2.35%) is higher than the bottom 25% of dividend payers in the UK market (1.91%).
High Dividend: DOCS's dividend (2.35%) is low compared to the top 25% of dividend payers in the UK market (5.28%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether DOCS's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if DOCS's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (30.4%), DOCS's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (34.5%), DOCS's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kenny Wilson (55 yo)
Mr. Kenneth Wilson, also known as Kenny, is Chief Executive Officer at Dr. Martens Limited and Dr. Martens plc since July 2018 and serves as its Director since January 5, 2021. He joined Dr. Martens Limite...
CEO Compensation Analysis
Compensation vs Market: Kenny's total compensation ($USD902.26K) is below average for companies of similar size in the UK market ($USD3.01M).
Compensation vs Earnings: Kenny's compensation has been consistent with company performance over the past year.
Experienced Management: DOCS's management team is considered experienced (2.5 years average tenure).
Experienced Board: DOCS's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Dr. Martens plc's employee growth, exchange listings and data sources
- Name: Dr. Martens plc
- Ticker: DOCS
- Exchange: LSE
- Founded: 1945
- Industry: Footwear
- Sector: Consumer Durables
- Implied Market Cap: UK£2.345b
- Shares outstanding: 1.00b
- Website: https://www.drmartensplc.com
Number of Employees
- Dr. Martens plc
- 28 Jamestown Road
- Greater London
- NW1 7BY
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/01 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.